Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FYX-051

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

NitrilesPyridines

Narrower (1)

topiroxostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
Background and ObjectivesTopiroxostat—a novel selective xanthine oxidoreductase inhibitor—has been reported to reduce serum urate… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2011
Highly Cited
2011
FYX-051: A Novel and Potent Hybrid-Type Inhibitor of Xanthine Oxidoreductase
4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (FYX-051) is a potent inhibitor of bovine milk xanthine… Expand
  • table 1
2010
2010
Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor
To clarify the toxicological aspects of FYX-051, a xanthine oxidoreductase inhibitor, which is currently being developed as a… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
2009
2009
Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Our previous study identified 2-[2-(2-methoxyethoxy)ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4] triazol-3-yl]benzonitrile (2… Expand
2009
2009
FYX-051, a Xanthine Oxidoreductase Inhibitor, Induces Nephropathy in Rats, but not in Monkeys
The present studies were performed to investigate the possible mechanism of marked species differences on nephropathy found in… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
2008
2008
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Xanthine oxidoreductase (XOR) catalyzes the reaction of hypoxanthine to xanthine and of xanthine to uric acid. Inhibitors of XOR… Expand
  • figure 3
2007
2007
Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor
In humans, orally administered 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051) is excreted mainly as… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 6
  • figure 7
2006
2006
Metabolic Profile of FYX-051 (4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the Rat, Dog, Monkey, and Human: Identification of N-Glucuronides and N-Glucosides
FYX-051, 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile, is a novel xanthine oxidoreductase inhibitor that can… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2006
2006
Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
To determine a rat strain appropriate for carcinogenicity testing of FYX-051, a xanthine oxidoreductase inhibitor, we performed a… Expand
2005
2005
Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
The possible mechanism of the underlying nephropathy found in the rat toxicity study of FYX-051, a xanthine oxidoreductase… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE